Exact Sciences Corp EXAS:NASDAQ

Last Price$85.17NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/11/19

Today's Change-0.13(0.15%)
Bid (Size)$83.50 (1)
Ask (Size)$86.01 (2)
Day Low / High$83.99 - 85.76
Volume1.1 M
 

View Biotechnology IndustryPeer Comparison as of 12/11/2019

 

Exact Sciences Corp ( NASDAQ )

Price: $85.17
Change: -0.13 (0.15%)
Volume: 1.1 M
4:00PM ET 12/11/2019
 
 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $118.79
Change: -3.05 (2.50%)
Volume: 522.8 K
3:59PM ET 12/11/2019
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $78.77
Change: -0.66 (0.83%)
Volume: 1.0 M
4:00PM ET 12/11/2019
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $113.25
Change: -0.40 (0.35%)
Volume: 1.7 M
3:59PM ET 12/11/2019
 
 

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $61.69
Change: -1.22 (1.94%)
Volume: 786.4 K
4:00PM ET 12/11/2019
 

Read more news Recent News

Insider Makes Significant Stock Sells in Exact Sciences (EXAS) Shares
10:18PM ET 11/26/2019 MT Newswires

There was a notable sale of shares of Exact Sciences by an insider today, as disclosed in a form 4 document filed with the SEC. One insider -- G Bradley...

Insider Trends: Insider Sales Continue 90-Day Trend at Exact Sciences
5:20PM ET 11/25/2019 MT Newswires

G Bradley Cole, General Manager - Diagnostics, executed a sale of 28,016 shares of Exact Sciences (EXAS) on Nov 21, 2019, for $2,251,926. After the Form 4...

Analyst Actions: Stifel Nicolaus Initiates Coverage on Exact Sciences With Buy Rating, $110 Price Target
8:36AM ET 11/15/2019 MT Newswires

Exact Sciences' (EXAS) average rating among analysts is a buy, with an average price target of $126. Price: 80.87, Change: +1.63, Percent Change: +2.06 ...

Exact Sciences Completes Acquisition of Genomic Health
12:07PM ET 11/08/2019 MT Newswires

Exact Sciences (EXAS), a provider of cancer screening and diagnostic tests, has completed the acquisition of Genomic Health (GHDX), according to a release...

Company Profile

Business DescriptionEXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI. View company web site for more details
Address441 Charmany Drive
Madison, Wisconsin 53719
Phone+1.608.284.5700
Number of Employees1,977
Recent SEC Filing11/27/20198-K
Chairman, President & Chief Executive OfficerKevin T. Conroy
Senior Vice President-OperationsAna Hooker
Chief Financial OfficerJeffrey T. Elliott
Co-Chief Medical Officer & Head-Medical AffairsBarry M. Berger

Company Highlights

Price Open$85.30
Previous Close$85.30
52 Week Range$53.06 - 123.99
Market Capitalization$11.1 B
Shares Outstanding129.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/20/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.71
Beta vs. S&P 500N/A
Revenue$454.5 M
Net Profit Margin-29.83%
Return on Equity-29.06%

Analyst Ratings as of 11/22/2019

Buy
11
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset